21 closest matches · ranked by relevance
Behçet's Syndrome
Primary: Area Under the Curve (AUC) for the Number of Oral Ulcers From Baseline Through Week 12 (AUC W0-12) — 222.14; 129.54 Ulcers*days — p=<0.0001
Autoimmune Connective Tissue Disorder · Immune System Diseases
Primary: Clinical Remission From Months 3-6 — 2 Participants
Behcet Syndrome
Primary: Number of Oral Ulcers at Day 85 — 2.0; 0.4 ulcers/participants — p=<0.0001
Behcet Disease
Primary: Rate of Recurrent Ocular Exacerbations in the Study Eye During 24 Weeks by Treatment — 7.7; 11.5; 7.7 Ocular Exacerbations
Behcet's Disease · Behcet Syndrome · Neuro-Behcet's Disease
Primary: Percentage of Participants With Complete Response at Week 30 — 54.5; 0; 100; 100 percentage of Complete Responders
Behcet's Disease
Primary: Number of Participants With Adverse Drug Reactions — 47; 5; 6; 1 Participants
Behcet Disease
Primary: Number of Participants With Attacks — 0 Participants
Behcet Syndrome · Behcet Disease · Mucocutaneous Ulceration
Primary: Comparison of Patients Experiencing a Sustained Response for Each Treatment Arm. — 13; 10; 12 patients with sustained response — p=0.404
Intestinal Behçet's Disease
Primary: Number of Participants With Marked Improvement at Week 24 — 9 participants
Erythema Multiforme
Primary: Erythema Multiforme Flares on Medication — 1.7 Number of flares
Spondyloarthritis · Enterocolitis
Primary: Change Lewis Score Index — -225 units on a scale
Arthritis, Reactive · Reiter Disease
Primary: Investigate Whether a 6 Month Course of Combined Antibiotics Was Effective Treatment. — 10; 7; 3 participants — p=0.01
Wegener's Granulomatosis
Primary: Safety of Abatacept - Number of Participants With Adverse Events — 7; 16; 14; 1 participants
Ankylosing Spondylitis
Primary: Occurence Rate of Uveitis Attacks in Participants Before Anti-TNF/GLM Treatment and After the Start of GLM Treatment — 0.08; 0.08 Ratio — p=1.0000
Takayasu's Arteritis · Giant Cell Arteritis
Primary: Primary Outcome - Relapse-free Survival (RFS) — 10; 14; 8; 10 Participants — p=0.049
Psoriasis
Primary: Change in Histology
Ocular Cicatricial Pemphigoid
Primary: Number of Participants With no Evidence of Further Scarring (Fosters Staging) at 16 Weeks — 0 participants
Primary Sjögren Syndrome
Primary: Change in The European League Against Rheumatism (EULAR) Sjogren's Syndrome Patient Reported Index (ESSPRI) Score From Baseline to Week 24 — -0.125 score on a scale
Chronic Beryllium Disease
Primary: Change in Beryllium Lymphocyte Proliferation Responses (BeLPT) From Baseline to Week 6 — 48.61; 9.33; 22.07; 3.8 Stimulation index
Uveitis
Primary: Change in Best-corrected Visual Acuity (Change in the Numbers of Letters Read From a Standard ETDRS Eye Chart) From Baseline to 24 Months in Eyes With Uveitis — 6.0; 3.2…
Uveitis
Primary: Number of Participants Experiencing a Treatment Response by Week 16 — 4; 2 Participants